Fox Run Management’s Aldeyra Therapeutics ALDX Stock Holding History

Fox Run Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$153K	Buy	90,964 +69,981	+334%	+$307K	0.03%	797
2025 Q4	$109K	Buy	+20,983	New	+$108K	0.02%	855
2025 Q2	–	Sell	-22,912	Closed	-$132K	–	831
2025 Q1	$132K	Buy	+22,912	New	+$135K	0.02%	845
2024 Q4	–	Sell	-19,002	Closed	-$102K	–	841
2024 Q3	$102K	Buy	+19,002	New	+$90.4K	0.02%	739
2023 Q4	–	Sell	-33,519	Closed	-$224K	–	704
2023 Q3	$224K	Buy	+33,519	New	+$249K	0.07%	532
2023 Q2	–	Sell	-23,317	Closed	-$232K	–	661
2023 Q1	$232K	Buy	23,317 +10,635	+84%	+$75.2K	0.08%	475
2022 Q4	$88.3K	Buy	+12,682	New	+$72.5K	0.04%	570

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fox Run Management's ALDX Position: Q1 2026 in Review

Fox Run Management increased its Aldeyra Therapeutics (ALDX) stake by 334% in Q1 2026, buying an estimated $307K and bringing the position to 90,964 shares worth $153K. The position accounts for 0.03% of the portfolio, ranked #797.

Fox Run Management first reported a position in ALDX in Q4 2022 and has held it in 7 quarters since. The position peaked at $232K in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Fox Run Management held 90,964 shares of Aldeyra Therapeutics worth $153K as of Q1 2026.
Fox Run Management bought 69,981 Aldeyra Therapeutics shares in Q1 2026, an estimated $307K.
Aldeyra Therapeutics made up 0.03% of Fox Run Management's portfolio in Q1 2026, its #797 holding.
Fox Run Management first reported a position in Aldeyra Therapeutics in Q4 2022 and has held it in 7 quarters since.
Fox Run Management's Aldeyra Therapeutics position peaked at $232K in Q1 2023.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.